



SOFIE
From start to clinic

FAP in Focus – Oncology and Horizons Beyond Cancer

DATE: Sunday, May 31, 2026
TIME: 6:30 pm – 8:30 pm PT
ROOM: Petree Hall D

VENUE: LA Convention Center
SNMMI 2026 Annual Meeting, Los Angeles, CA
Refreshments will be provided

In this informative session, we will share progress on SOFIE's Phase 3 clinical trials for [¹⁸F]FAPI-74 as a diagnostic radiopharmaceutical. Academic and industry representatives will also share their perspectives on current FAP targeting in non-oncology and therapeutic use. The session will conclude with a panel discussion on the overall FAP landscape.

SCIENTIFIC AGENDA	SPEAKERS
SOFIE's [¹⁸F]FAPI-74 Phase 3 Diagnostic Clinical Studies	FAP-IGO: Omar Partida (RadNet) FAP-PRO: Gary Ulaner, MD, PhD (Hoag Family Cancer Institute)
FAP Targeting in Non-Oncology	Sanjay Jain, MD (Cincinnati Children's Hospital)
FAP Targeting in Therapy	Darshan Dalal, MD, PhD (Actithera) Jessica Jensen (Eli Lilly)
Panel – FAP Landscape	Moderated by: Andrew Scott, MBBS (Hons), MD, FRACP, FAHMS, FAICD, FAANMS (Olivia Newton-John Cancer Research Institute)
Q&A	All

FAP is investigational and has not been approved by the U.S. Food and Drug Administration (FDA). FAP's safety and efficacy have not been established. This session is provided for informational purposes only and is intended solely for use by healthcare professionals, clinical trial investigators, and regulatory authorities. It is not intended as medical advice or an offer for sale or commercial promotion. Any use of FAP is subject to applicable regulatory approval processes and clinical trial protocols.